Stereotaxis, Inc. (STXS) Q2 2026 Earnings Call Transcript
Stereotaxis, Inc. (STXS) Q2 2026 Earnings Call Transcript
Stereotaxis Q2 Earnings Call Highlights
Stereotaxis NYSEAMERICAN: STXS reported second-quarter 2026 revenue of $7.7 million, as growth in sales of its robotic catheter portfolio helped lift recurring revenue to a multiyear high despite lower system revenue and continued supply constraints.
Stereotaxis Inc. (STXS) Reports Q2 Loss, Lags Revenue Estimates
Stereotaxis Inc. (STXS) came out with a quarterly loss of $0.05 per share versus the Zacks Consensus Estimate of a loss of $0.03. This compares to a loss of $0.05 per share a year ago.
Stereotaxis Q1 Earnings Call Highlights
Stereotaxis NYSEAMERICAN: STXS said its first-quarter results did not yet reflect what management described as a major commercial transition driven by new regulatory approvals, new catheter products and the launch of its GenesisX robotic system.
Stereotaxis, Inc. (STXS) Q1 2026 Earnings Call Transcript
Stereotaxis, Inc. (STXS) Q1 2026 Earnings Call Transcript
Stereotaxis Inc. (STXS) Reports Q1 Loss, Lags Revenue Estimates
Stereotaxis Inc. (STXS) came out with a quarterly loss of $0.03 per share versus the Zacks Consensus Estimate of a loss of $0.04. This compares to a loss of $0.07 per share a year ago.
Stereotaxis Stock Up on First U.S. MAGiC Procedures Post Approval
STXS stock gains after first U.S. MAGiC procedures, marking a key milestone in robotic cardiac care and boosting its growth outlook.
STXS to Acquire Robocath to Lead in Endovascular Robotics Market
Stereotaxis expands in robotic surgery with Robocath acquisition, aiming to build a comprehensive endovascular platform and unlock growth opportunities.
STXS Gains on FDA Nod for Synchrony System, Expands Digital Surgery
STXS jumps on FDA clearance of Synchrony system, a 4K platform integrating cath lab tech with cloud connectivity to boost workflow, precision and digital surgery.
Stereotaxis: Medical Robotics Upside Offsets Cash Burn And Execution Risks
Stereotaxis targets early-stage endovascular robotics with differentiated magnetic navigation for electrophysiology and other minimally invasive procedures. Their MAGiC catheter recently received FDA approval, which I think strengthens STXS's razor-and-blade model by adding recurring disposable revenues. At this point, the bull case rests on STXS growing its early adoption into durable revenues across electrophysiology, endovascular, and connectivity applications.
Stereotaxis, Inc. (STXS) Q4 2025 Earnings Call Transcript
Stereotaxis, Inc. (STXS) Q4 2025 Earnings Call Transcript
Stereotaxis Inc. (STXS) Reports Q4 Loss, Lags Revenue Estimates
Stereotaxis Inc. (STXS) came out with a quarterly loss of $0.06 per share in line with the Zacks Consensus Estimate. This compares to a loss of $0.09 per share a year ago.
